Core Insights - The company reported record-breaking quarterly results for the second consecutive quarter, driven by new customer volume additions and effective cost management [2][11] - The company is focusing on expanding its product offerings, particularly in ultra-filtered milk-based high-protein products, due to strong customer interest [1][24] - The company has successfully managed to optimize its supply chain and control expenses, contributing to significant year-over-year growth in net sales and adjusted EBITDA [11][12] Financial Performance - The adjusted EBITDA for the beverage solutions and SS&T segments reached $26.2 million, marking a 14% increase from the previous quarter and an 84% increase year-over-year [1] - Consolidated net sales increased by 61% compared to the third quarter of 2024, with a reported net loss of $19.1 million attributed to ongoing investments in the Conway facility [11][12] - The company expects consolidated adjusted EBITDA for 2025 to be between $60 million and $65 million, consistent with earlier guidance [16] Operational Developments - The Conway facility has reached production levels nearing 80% of its planned capacity, with significant investments made to enhance operational efficiency [5][12] - A new $30 million capital infusion from core shareholders has been secured, which will support operational delivery and address working capital needs due to elevated coffee prices and tariffs [9][15] - The company is optimistic about future growth opportunities, particularly in the ultra-filtered milk segment, which is expected to compete with traditional ready-to-drink coffee products [24][25] Market Dynamics - The company faces challenges from historically high coffee prices and tariffs, which have impacted gross margins and consumer demand [14][28] - There is uncertainty regarding a key customer's commitment to single-serve cup volumes due to an ongoing M&A transaction, which may affect future sales [17][30] - Despite these challenges, the company remains confident in its ability to replace any lost volume with new customer acquisitions and existing customer expansions [19][39]

Core Insights - Canada Goose reported a 1.8% increase in total revenue to CAD 272.6 million for the second quarter of fiscal 2026, with direct-to-consumer (DTC) revenue growing by 21.8% to CAD 126.6 million, driven by a 10.2% increase in DTC comparable sales [3][9] - The company experienced an operating loss of CAD 17.6 million, compared to an operating income of CAD 1.6 million in the prior year, primarily due to increased selling, general, and administrative (SG&A) expenses [3][9] - Net loss attributable to shareholders was CAD 15.2 million, or CAD 0.16 per share, compared to a net income of CAD 5.4 million, or CAD 0.06 per share, in the same quarter last year [9][20] Business Highlights - The launch of the Fall/Winter 2025 collection emphasized modern urban storytelling and bold designs, enhancing brand engagement through partnerships, including a collaboration with NBA MVP Shai Gilgeous-Alexander [2][3] - The company relocated its Paris store to Champs-Élysées, enhancing the consumer experience with a new design and curated selections from its art collection [3] - Canada Goose opened one new store during the quarter, bringing the total permanent store count to 77 [3] Financial Performance - DTC revenue growth was attributed to improved execution, a stronger mix of in-season products, and consistent marketing efforts [3] - Wholesale revenue decreased by 1.0% to CAD 135.9 million, aligning with revenue from the comparative quarter [3] - Other revenue saw a significant decline of 62.0% to CAD 10.1 million, primarily due to fewer Friends & Family events and employee sales [3] Balance Sheet and Debt Management - Inventory decreased by 3% year-over-year to CAD 460.7 million, reflecting higher demand and proactive inventory management [4] - The company ended the quarter with net debt of CAD 707.1 million, down from CAD 826.4 million a year earlier, due to disciplined working capital management and cash generated from operations [5] Corporate Governance - Stephen Gunn retired from the Board of Directors, and Belinda Wong was appointed as an audit committee financial expert [6] Shareholder Returns - Canada Goose announced an early renewal of its normal course issuer bid (NCIB), allowing for the purchase of up to 4,578,677 subordinate voting shares over the next twelve months [7][8]

Financial Data and Key Metrics Changes - The company reported net sales of $375 million for Q2 2025, reflecting a 7.6% increase year-over-year [27] - Adjusted EBITDA margin improved to 13.1%, marking the highest level in nearly two years [6][30] - Gross margin decreased to 31.2% from 31.8% year-over-year, while adjusted gross margin was 31.3% compared to 31.9% in the prior year [27][28] Business Line Data and Key Metrics Changes - In the Powered Vehicles Group (PVG), net sales increased by $4.9 million to $123.5 million, driven by growth in the motorized two-wheel business [11] - The Aftermarket Applications Group (AAG) saw net sales rise 6.5% to $114.1 million, attributed to increased demand for aftermarket products [14] - The Specialty Sports Group (SSG) reported an 11% increase in net sales to $137.2 million, supported by strong bike business performance [18] Market Data and Key Metrics Changes - The company noted that the consumer discretionary environment is stabilizing, which is expected to support enhanced profitability [10] - Tariff impacts were highlighted, with an increase in expected tariff costs from $38 million to $50 million for the year, affecting various segments [33][49] Company Strategy and Development Direction - The company is focused on four key initiatives: footprint consolidation, portfolio optimization, working capital management, and a $25 million cost reduction program [7][9] - Emphasis on product innovation and R&D is seen as crucial for maintaining market share and driving long-term growth [6][10] - The company is strategically expanding into new OEMs and industries, particularly in the motorcycle and electric vehicle sectors [11][44] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to navigate macro challenges and achieve growth through operational excellence and innovation [10][35] - The outlook for the second half of 2025 remains positive, with expectations for improved order books and product launches [25][32] - Management acknowledged ongoing tariff pressures but emphasized efforts to mitigate these impacts through various strategies [33][87] Other Important Information - The company is on track to reduce net leverage to below three times by year-end, with a focus on debt reduction [31] - Free cash flow generation is anticipated to be approximately $80 million for the full year [32] Q&A Session Summary Question: What is driving the raised sales guidance? - Management indicated that the entire enterprise is performing well, leading to increased confidence in the second half of the year [41][42] Question: How is the company addressing the higher tariff impact? - The increase in tariff impact is attributed to both the Marucci mix and products from Taiwan, with specific allocations provided for each segment [49] Question: Is there directional improvement in the powersports market? - Management noted that while stability is returning to the powersports market, interest rate improvements are necessary for significant growth [50] Question: What is the outlook for the bike business? - The bike business is expected to grow, with a focus on stabilizing inventory levels and preparing for new product launches [63][67] Question: What are the growth vectors for Marucci? - Management highlighted global growth, diversification in product lines, and expansion into softball as key growth areas for Marucci [78][81]

Financial Data and Key Metrics Changes - Revenue for Q4 2024 was $100.3 million, a 17% increase compared to Q4 2023, driven primarily by dispensary revenue [21] - Full year 2024 revenue reached $393 million, representing a 21.3% increase from 2023 [25] - Gross profit for Q4 2024 was $14.6 million, a 2% increase year-over-year, while full year gross profit was $54 million, a 9.4% decrease from 2023 [22][25] - Net loss for Q4 2024 was $13 million, an improvement of $5.6 million compared to Q4 2023, while the full year net loss was $64.6 million, a decrease of $18.4 million from 2023 [23][27] - Adjusted EBITDA for Q4 2024 was negative $7.8 million, compared to negative $6.3 million in Q4 2023, and for the full year, it was negative $35.7 million [23][27] Business Line Data and Key Metrics Changes - Value-based patient services saw significant growth with six new contracts totaling over 270,000 lives launched in Q3 and Q4 2024 [9] - Pharmacy and medically integrated dispensaries generated $48 million in Q4 and $180 million for the full year, reflecting a 73% annualized growth [10] - SG&A expenses decreased by 12% in Q4 2024 compared to Q4 2023, demonstrating operational efficiency [12] Market Data and Key Metrics Changes - The company expanded its operations outside California, signing two new contracts in Florida during Q4 2024, totaling over 200,000 lives [9] - The company is positioned to handle substantial growth in new markets without increasing overhead costs [31] Company Strategy and Development Direction - The company aims to achieve profitability and positive cash flow by the end of 2025, focusing on operational management and strategic market expansion [8][39] - A key strategy includes optimizing the cost structure and enhancing financial flexibility through debt restructuring and capital raises [16][18] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in crossing the line to profitability by the end of 2025, despite 2024 not meeting expectations [8] - The company anticipates a gradual reduction in losses throughout 2025, with expectations of positive EBITDA in Q4 [35] Other Important Information - Cash and cash equivalents increased to $49.7 million by the end of Q4 2024, aided by working capital management [28] - The company successfully amended its facility agreement, including a $20 million principal paydown of outstanding debt [16] Q&A Session Summary Question: What are the significant moving factors for 2025 guidance? - Growth in capitation contracts and organic growth in fee-for-service and dispensary are essential for achieving targets [45] Question: Will patient service be a meaningful growth driver in 2025? - Yes, the capitation segment will be the primary driver of overall profitability [48] Question: What is the capacity of new clinics in Florida compared to California? - California clinics are operating at about 75% capacity, while Florida clinics are at approximately 40% capacity [54] Question: Any thoughts on the recent reimbursement landscape? - General macro trends in the oncology industry are favorable, with potential benefits from changes related to drug pricing [59]

Financial Data and Key Metrics Changes - For Q4 2024, total revenue was $702.8 million, flat compared to Q4 2023, while full year revenue reached $2.79 billion, a slight increase of just over 1% [61][63] - Adjusted EBITDA for Q4 was $40.4 million, totaling $161.1 million for the full year, reflecting a decrease of approximately 20% [11][62] - Consolidated net loss for Q4 was $23.5 million, while adjusted net income was $2.7 million, or $0.19 per share [63] Business Line Data and Key Metrics Changes - The NEMT segment, representing 70% of total revenue, generated $495 million in revenue, remaining flat year over year [64] - Personal Care Services (PCS) revenue increased by 3% year over year to $186.6 million, driven by a 3.5% growth in revenue per hour [68] - Remote Patient Monitoring (RPM) revenue was $19.2 million, representing 3% of total revenue but 16% of adjusted EBITDA [69] Market Data and Key Metrics Changes - Average monthly members in the NEMT segment decreased by approximately 11% year over year, while trip volume increased by 8.5% compared to a year ago [64] - The total addressable market for NEMT is estimated to exceed $6 billion, with an annual MCO revenue base of $1 billion entering 2025 [31] Company Strategy and Development Direction - The company aims to strengthen technology-enabled platforms across NEMT, personal care, and monitoring while executing strategic financial initiatives and divesting platforms [12][22] - A focus on monetizing select segments and unlocking value is emphasized, with a strategic alternatives committee established to oversee the divestiture process [22][23] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the unprecedented challenges faced in 2024, including Medicaid redetermination and increased healthcare utilization, but expressed confidence in navigating these disruptions [8][9] - The company is optimistic about future growth opportunities, particularly in the MCO segment, with a win rate exceeding 90% over the past two years [31] Other Important Information - The company secured an incremental $75 million term loan and $30 million in new second lien notes to enhance financial flexibility [14][60] - New board appointments were made to enhance expertise in operational efficiency and technology innovation [15][20] Q&A Session Summary Question: How does ModivCare Inc.'s exposure to Medicaid affect fee-for-service contracts? - Management expects that any Medicaid cuts will primarily affect healthier members, and they are currently negotiating to reset payments based on member mix [78][80] Question: Can you provide an update on the sale process? - Management indicated that discussions are ongoing and they are encouraged by the interest in their platforms, but specific timing for sales was not disclosed [83][84] Question: What is the current membership status in NEMT and monitoring? - Membership in NEMT has decreased significantly, with expectations of recovery as new contracts are pursued [89][90] Question: What are the expectations for cash flow in 2025? - Management confirmed that they expect a return to positive free cash flow in the latter half of 2025, with improvements in contract structures aiding liquidity [112][117] Question: How will the transition from shared risk to fee-for-service contracts impact revenue? - Approximately 25% of revenue is expected to shift to fee-for-service contracts, which will help stabilize cash flow and reduce working capital shifts [124][126]